
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PSPH CRISPR/Cas9 KO Plasmid (h) | sc-403897 | 20 µg | $397.00 |
Phosphoserine phosphatase (PSPH) catalyzes the final step of the phosphorylated serine biosynthesis pathway, converting O-phospho-L-serine to L-serine and inorganic phosphate. By controlling intracellular serine availability, PSPH supports one-carbon metabolism and nucleotide synthesis, redox balance through glutathione production, and lipid synthesis, linking amino acid metabolism to proliferative and stress-response programs. PSPH activity interfaces with metabolic rewiring observed in rapidly dividing cells and is frequently examined alongside PHGDH and PSAT1 within the serine–glycine axis. Dysregulated expression of PSPH has been associated with altered metabolic phenotypes in cancer and other disorders characterized by perturbed amino acid and one-carbon metabolism, making it relevant for mechanistic studies of metabolic vulnerability.
PSPH CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PSPH gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PSPH together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PSPH open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PSPH protein expression.
This CRISPR knockout system enables efficient generation of PSPH-deficient cell models for investigation of PSPH signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.